Modality
Radioligand
MOA
CGRPant
Target
VEGF
Pathway
Amyloid
LN
Development Pipeline
Preclinical
~Jan 2023
→ ~Apr 2024
Phase 1
Jul 2024
→ Nov 2030
Phase 1Current
NCT04034490
2,540 pts·LN
2024-07→2030-11·Active
2,540 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-11-254.7y awayInterim· LN
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Active
Catalysts
Interim
2030-11-25 · 4.7y away
LN
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04034490 | Phase 1 | LN | Active | 2540 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 |